Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

High control rates of proton- and carbon-ion-beam treatment with intensity-modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg Ion Beam Therapy Center.

Mattke M, Vogt K, Bougatf N, Welzel T, Oelmann-Avendano J, Hauswald H, Jensen A, Ellerbrock M, Jäkel O, Haberer T, Herfarth K, Debus J, Uhl M.

Cancer. 2018 May 1;124(9):2036-2044. doi: 10.1002/cncr.31298. Epub 2018 Feb 22.

PMID:
29469932
2.

Proton and helium ion radiotherapy for meningioma tumors: a Monte Carlo-based treatment planning comparison.

Tessonnier T, Mairani A, Chen W, Sala P, Cerutti F, Ferrari A, Haberer T, Debus J, Parodi K.

Radiat Oncol. 2018 Jan 9;13(1):2. doi: 10.1186/s13014-017-0944-3.

3.

Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation.

Klein C, Dokic I, Mairani A, Mein S, Brons S, Häring P, Haberer T, Jäkel O, Zimmermann A, Zenke F, Blaukat A, Debus J, Abdollahi A.

Radiat Oncol. 2017 Dec 29;12(1):208. doi: 10.1186/s13014-017-0939-0.

4.

Sequential proton boost after standard chemoradiation for high-grade glioma.

Adeberg S, Bernhardt D, Harrabi SB, Uhl M, Paul A, Bougatf N, Verma V, Unterberg A, Wick W, Haberer T, Combs SE, Herfarth K, Debus J, Rieken S.

Radiother Oncol. 2017 Nov;125(2):266-272. doi: 10.1016/j.radonc.2017.09.040. Epub 2017 Oct 16.

PMID:
29050959
5.

Helium ions at the heidelberg ion beam therapy center: comparisons between FLUKA Monte Carlo code predictions and dosimetric measurements.

Tessonnier T, Mairani A, Brons S, Sala P, Cerutti F, Ferrari A, Haberer T, Debus J, Parodi K.

Phys Med Biol. 2017 Aug 1;62(16):6784-6803. doi: 10.1088/1361-6560/aa7b12.

PMID:
28762335
6.

Dosimetric verification in water of a Monte Carlo treatment planning tool for proton, helium, carbon and oxygen ion beams at the Heidelberg Ion Beam Therapy Center.

Tessonnier T, Böhlen TT, Ceruti F, Ferrari A, Sala P, Brons S, Haberer T, Debus J, Parodi K, Mairani A.

Phys Med Biol. 2017 Jul 31;62(16):6579-6594. doi: 10.1088/1361-6560/aa7be4.

PMID:
28650846
7.

Experimental dosimetric comparison of 1H, 4He, 12C and 16O scanned ion beams.

Tessonnier T, Mairani A, Brons S, Haberer T, Debus J, Parodi K.

Phys Med Biol. 2017 May 21;62(10):3958-3982. doi: 10.1088/1361-6560/aa6516. Epub 2017 Apr 13.

PMID:
28406796
8.

Optimizing the modified microdosimetric kinetic model input parameters for proton and 4He ion beam therapy application.

Mairani A, Magro G, Tessonnier T, Böhlen TT, Molinelli S, Ferrari A, Parodi K, Debus J, Haberer T.

Phys Med Biol. 2017 Jun 7;62(11):N244-N256. doi: 10.1088/1361-6560/aa6be9. Epub 2017 Apr 6.

PMID:
28384125
9.

Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines.

Dehne S, Fritz C, Rieken S, Baris D, Brons S, Haberer T, Debus J, Weber KJ, Schmid TE, Combs SE, Habermehl D.

Front Oncol. 2017 Mar 13;7:35. doi: 10.3389/fonc.2017.00035. eCollection 2017.

10.

A phenomenological relative biological effectiveness approach for proton therapy based on an improved description of the mixed radiation field.

Mairani A, Dokic I, Magro G, Tessonnier T, Bauer J, Böhlen TT, Ciocca M, Ferrari A, Sala PR, Jäkel O, Debus J, Haberer T, Abdollahi A, Parodi K.

Phys Med Biol. 2017 Feb 21;62(4):1378-1395. doi: 10.1088/1361-6560/aa51f7. Epub 2017 Jan 23.

PMID:
28114106
11.

Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma.

Harrabi SB, Bougatf N, Mohr A, Haberer T, Herfarth K, Combs SE, Debus J, Adeberg S.

Strahlenther Onkol. 2016 Nov;192(11):759-769. Epub 2016 Jun 30.

12.

Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma : A dosimetric comparison.

Adeberg S, Harrabi SB, Bougatf N, Bernhardt D, Rieber J, Koerber SA, Syed M, Sprave T, Mohr A, Abdollahi A, Haberer T, Combs SE, Herfarth K, Debus J, Rieken S.

Strahlenther Onkol. 2016 Nov;192(11):770-779. Epub 2016 Jun 22.

PMID:
27334276
13.

Next generation multi-scale biophysical characterization of high precision cancer particle radiotherapy using clinical proton, helium-, carbon- and oxygen ion beams.

Dokic I, Mairani A, Niklas M, Zimmermann F, Chaudhri N, Krunic D, Tessonnier T, Ferrari A, Parodi K, Jäkel O, Debus J, Haberer T, Abdollahi A.

Oncotarget. 2016 Aug 30;7(35):56676-56689. doi: 10.18632/oncotarget.10996.

14.

Biologically optimized helium ion plans: calculation approach and its in vitro validation.

Mairani A, Dokic I, Magro G, Tessonnier T, Kamp F, Carlson DJ, Ciocca M, Cerutti F, Sala PR, Ferrari A, Böhlen TT, Jäkel O, Parodi K, Debus J, Abdollahi A, Haberer T.

Phys Med Biol. 2016 Jun 7;61(11):4283-99. doi: 10.1088/0031-9155/61/11/4283. Epub 2016 May 20.

PMID:
27203864
15.

Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.

Habl G, Uhl M, Katayama S, Kessel KA, Hatiboglu G, Hadaschik B, Edler L, Tichy D, Ellerbrock M, Haberer T, Wolf MB, Schlemmer HP, Debus J, Herfarth K.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):435-43. doi: 10.1016/j.ijrobp.2016.02.025. Epub 2016 Feb 12.

PMID:
27084659
16.

S-phase-specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro.

Harrabi SB, Adeberg S, Winter M, Haberer T, Debus J, Weber KJ.

J Radiat Res. 2016 Mar;57(2):110-4. doi: 10.1093/jrr/rrv097. Epub 2016 Jan 7.

17.

Data-driven RBE parameterization for helium ion beams.

Mairani A, Magro G, Dokic I, Valle SM, Tessonnier T, Galm R, Ciocca M, Parodi K, Ferrari A, Jäkel O, Haberer T, Pedroni P, Böhlen TT.

Phys Med Biol. 2016 Jan 21;61(2):888-905. doi: 10.1088/0031-9155/61/2/888. Epub 2016 Jan 7.

PMID:
26740518
18.

COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results of the Prospective Phase 2 Trial.

Jensen AD, Nikoghosyan AV, Lossner K, Haberer T, Jäkel O, Münter MW, Debus J.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):37-46. doi: 10.1016/j.ijrobp.2015.05.013. Epub 2015 May 19.

PMID:
26279022
19.

High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy.

Jensen AD, Poulakis M, Nikoghosyan AV, Welzel T, Uhl M, Federspil PA, Freier K, Krauss J, Höss A, Haberer T, Jäkel O, Münter MW, Schulz-Ertner D, Huber PE, Debus J.

Radiother Oncol. 2016 Feb;118(2):272-80. doi: 10.1016/j.radonc.2015.05.010. Epub 2015 Jul 8.

PMID:
26164774
20.

Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival.

Jensen AD, Nikoghosyan AV, Poulakis M, Höss A, Haberer T, Jäkel O, Münter MW, Schulz-Ertner D, Huber PE, Debus J.

Cancer. 2015 Sep 1;121(17):3001-9. doi: 10.1002/cncr.29443. Epub 2015 Jun 4.

Supplemental Content

Loading ...
Support Center